VPC-14228

• CAT Number: I012135
• CAS Number: 19983-28-9
• Molecular Formula: C13H14N2OS
• Molecular Weight: 246.33
• Purity: ≥95%
• Synonyms: 4-(4-phenyl-1,3-thiazol-2-yl)morpholine
• InChI: InChI=1S/C13H14N2OS/c1-2-4-11(5-3-1)12-10-17-13(14-12)15-6-8-16-9-7-15/h1-5,10H,6-9H2
• InChIKey: MRNNJVNMXOZEQC-UHFFFAOYSA-N
• SMILES: C1COCCN1C2=NC(=CS2)C3=CC=CC=C3

VPC-14228 (Cat No.: I012135) is a small-molecule inhibitor developed to target the androgen receptor (AR), specifically its DNA-binding domain, offering a novel approach to disrupting AR signaling in prostate cancer. Unlike traditional AR antagonists that bind the ligand-binding domain, VPC-14228 interferes with AR-mediated transcriptional activity at the genomic level. This mechanism makes it especially valuable in treating castration-resistant prostate cancer (CRPC), where resistance to conventional therapies is common. Preclinical studies demonstrate its potential efficacy and specificity, positioning it as a promising therapeutic candidate.

Reference

[1]. Kush Dalal, et al. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer. J Biol Chem. 2014 Sep 19;289(38):26417-26429.
[Content Brief]